Opus Genetics Secures Up to $155M in Non-Dilutive Financing to Advance Gene Therapies for Inherited Retinal Disease

Precision capital doesn’t wander. It picks its spot, places its chips, and waits for the math to do its job. Opus Genetics just drew that line in ink, and Oberland Capital Management met it without hesitation, committing up to $155M in primarily non-dilutive financing to accelerate a gene therapy pipeline aimed at inherited retinal diseases. Vision isn’t a metaphor here. It’s the product. And the stakes are as real as it gets.

Durham isn’t new to biotech, but Opus Genetics is playing a sharper game. Founded in 2018 with roots tied to Foundation Fighting Blindness and RD Fund, this isn’t a spray-and-pray platform story. This is targeted, genetic precision aimed straight at inherited retinal diseases. George Magrath, CEO is steering the machine, with Ben Yerxa, President still in the mix, carrying the original blueprint forward. And in the lab where theory either earns its keep or gets buried, Ash Jayagopal, CSO is translating code into candidates that actually move.

Let’s talk structure, because structure tells you how smart the money really is. This isn’t dilution dressed up as momentum. It’s a $35M upfront push, a $5M equity check priced with intent, and milestone-based tranches that reward execution, not promises. The kind of deal that says, “We’ll keep funding you… if you keep delivering.” Backed in part by a non-core asset, which is just a clean way of saying they protected the crown jewels while still getting the fuel.

And the pipeline? OPGx-LCA5 and OPGx-BEST1 aren’t science fair projects. They’re in position for pivotal studies and potential regulatory paths, while RDH12, MERTK, and RHO line up behind them like disciplined hitters waiting for their turn at the plate. 3 more programs expected in the clinic by 2027. That’s not a maybe. That’s a schedule.

Here’s the part people miss when they skim the headline and move on. Non-dilutive capital extending runway into 2029 isn’t just financial breathing room. It’s strategic patience. It means fewer rushed decisions, tighter trials, better data. It means Opus Genetics gets to build, not scramble. And in biotech, that difference shows up in outcomes, not press releases.

Oberland Capital saw it. Backed it. Structured it like adults in a market that sometimes forgets how. And Opus Genetics? They didn’t just raise money. They bought time, focus, and a real shot at changing what patients see when they open their eyes tomorrow.